FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3144539302> ?p ?o ?g. }

• W3144539302 endingPage "1071.e11" @default.
• W3144539302 startingPage "1061" @default.
• W3144539302 abstract "IntroductionThere is no detailed comparison of allergen-specific immunoglobulin responses following sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT).ObjectiveWe sought to compare nasal and systemic timothy grass pollen (TGP)-specific antibody responses during 2 years of SCIT and SLIT and 1 year after treatment discontinuation in a double-blind, double-dummy, placebo-controlled trial.MethodsNasal fluid and serum were obtained yearly (per-protocol population, n = 84). TGP-specific IgA1, IgA2, IgG4, IgG, and IgE were measured in nasal fluids by ELISA. TGP-specific IgA1, IgA2, and Phleum pratense (Phl p)1, 2, 4, 5b, 6, 7, 11, and 12 IgE and IgG4 were measured in sera by ELISA and ImmunoCAP, respectively.ResultsAt years 2 and 3, TGP-IgA1/2 levels in nasal fluid were elevated in SLIT compared with SCIT (4.2- and 3.0-fold for IgA1, 2.0- and 1.8-fold for IgA2, respectively; all P < .01). TGP-IgA1 level in serum was elevated in SLIT compared with SCIT at years 1, 2, and 3 (4.6-, 5.1-, and 4.7-fold, respectively; all P < .001). Serum TGP-IgG level was higher in SCIT compared with SLIT (2.8-fold) at year 2. Serum TGP-IgG4 level was higher in SCIT compared with SLIT at years 1, 2, and 3 (10.4-, 27.4-, and 5.1-fold, respectively; all P < .01). Serum IgG4 levels to Phl p1, 2, 5b, and 6 were increased at years 1, 2, and 3 in SCIT and SLIT compared with placebo (Phl p1: 11.8- and 3.9-fold; Phl p2: 31.6- and 4.4-fold; Phl p5b: 135.5- and 5.3-fold; Phl p6: 145.4- and 14.7-fold, respectively, all at year 2 when levels peaked; P < .05). IgE to TGP in nasal fluid increased in the SLIT group at year 2 but not at year 3 compared with SCIT (2.8-fold; P = .04) and placebo (3.1-fold; P = .02). IgA to TGP and IgE and IgG4 to TGP components stratified participants according to treatment group and clinical response.ConclusionsThe observed induction of IgA1/2 in SLIT and IgG4 in SCIT suggest key differences in the mechanisms of action. There is no detailed comparison of allergen-specific immunoglobulin responses following sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT). We sought to compare nasal and systemic timothy grass pollen (TGP)-specific antibody responses during 2 years of SCIT and SLIT and 1 year after treatment discontinuation in a double-blind, double-dummy, placebo-controlled trial. Nasal fluid and serum were obtained yearly (per-protocol population, n = 84). TGP-specific IgA1, IgA2, IgG4, IgG, and IgE were measured in nasal fluids by ELISA. TGP-specific IgA1, IgA2, and Phleum pratense (Phl p)1, 2, 4, 5b, 6, 7, 11, and 12 IgE and IgG4 were measured in sera by ELISA and ImmunoCAP, respectively. At years 2 and 3, TGP-IgA1/2 levels in nasal fluid were elevated in SLIT compared with SCIT (4.2- and 3.0-fold for IgA1, 2.0- and 1.8-fold for IgA2, respectively; all P < .01). TGP-IgA1 level in serum was elevated in SLIT compared with SCIT at years 1, 2, and 3 (4.6-, 5.1-, and 4.7-fold, respectively; all P < .001). Serum TGP-IgG level was higher in SCIT compared with SLIT (2.8-fold) at year 2. Serum TGP-IgG4 level was higher in SCIT compared with SLIT at years 1, 2, and 3 (10.4-, 27.4-, and 5.1-fold, respectively; all P < .01). Serum IgG4 levels to Phl p1, 2, 5b, and 6 were increased at years 1, 2, and 3 in SCIT and SLIT compared with placebo (Phl p1: 11.8- and 3.9-fold; Phl p2: 31.6- and 4.4-fold; Phl p5b: 135.5- and 5.3-fold; Phl p6: 145.4- and 14.7-fold, respectively, all at year 2 when levels peaked; P < .05). IgE to TGP in nasal fluid increased in the SLIT group at year 2 but not at year 3 compared with SCIT (2.8-fold; P = .04) and placebo (3.1-fold; P = .02). IgA to TGP and IgE and IgG4 to TGP components stratified participants according to treatment group and clinical response. The observed induction of IgA1/2 in SLIT and IgG4 in SCIT suggest key differences in the mechanisms of action." @default.
• W3144539302 created "2021-04-13" @default.
• W3144539302 creator A5007149092 @default.
• W3144539302 creator A5011069925 @default.
• W3144539302 creator A5015647447 @default.
• W3144539302 creator A5026752464 @default.
• W3144539302 creator A5028359667 @default.
• W3144539302 creator A5028378271 @default.
• W3144539302 creator A5028455005 @default.
• W3144539302 creator A5030496904 @default.
• W3144539302 creator A5040778237 @default.
• W3144539302 creator A5043192106 @default.
• W3144539302 creator A5048817166 @default.
• W3144539302 creator A5060457096 @default.
• W3144539302 creator A5063479502 @default.
• W3144539302 creator A5069522355 @default.
• W3144539302 creator A5073520094 @default.
• W3144539302 creator A5076383043 @default.
• W3144539302 date "2021-10-01" @default.
• W3144539302 modified "2023-10-17" @default.
• W3144539302 title "Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy" @default.
• W3144539302 cites W1576438536 @default.
• W3144539302 cites W1577022278 @default.
• W3144539302 cites W1772901658 @default.
• W3144539302 cites W1985662851 @default.
• W3144539302 cites W1992236923 @default.
• W3144539302 cites W2005724569 @default.
• W3144539302 cites W2009280170 @default.
• W3144539302 cites W2014513314 @default.
• W3144539302 cites W2018297739 @default.
• W3144539302 cites W2022429437 @default.
• W3144539302 cites W2028803867 @default.
• W3144539302 cites W2046574729 @default.
• W3144539302 cites W2104772500 @default.
• W3144539302 cites W2124827015 @default.
• W3144539302 cites W2148459384 @default.
• W3144539302 cites W2153011983 @default.
• W3144539302 cites W2312829609 @default.
• W3144539302 cites W232013779 @default.
• W3144539302 cites W2588697122 @default.
• W3144539302 cites W2754428040 @default.
• W3144539302 cites W2767225941 @default.
• W3144539302 cites W2773607015 @default.
• W3144539302 cites W2900887130 @default.
• W3144539302 cites W2913428120 @default.
• W3144539302 cites W2997794562 @default.
• W3144539302 doi "https://doi.org/10.1016/j.jaci.2021.03.030" @default.
• W3144539302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33819508" @default.
• W3144539302 hasPublicationYear "2021" @default.
• W3144539302 type Work @default.
• W3144539302 sameAs 3144539302 @default.
• W3144539302 citedByCount "33" @default.
• W3144539302 countsByYear W31445393022021 @default.
• W3144539302 countsByYear W31445393022022 @default.
• W3144539302 countsByYear W31445393022023 @default.
• W3144539302 crossrefType "journal-article" @default.
• W3144539302 hasAuthorship W3144539302A5007149092 @default.
• W3144539302 hasAuthorship W3144539302A5011069925 @default.
• W3144539302 hasAuthorship W3144539302A5015647447 @default.
• W3144539302 hasAuthorship W3144539302A5026752464 @default.
• W3144539302 hasAuthorship W3144539302A5028359667 @default.
• W3144539302 hasAuthorship W3144539302A5028378271 @default.
• W3144539302 hasAuthorship W3144539302A5028455005 @default.
• W3144539302 hasAuthorship W3144539302A5030496904 @default.
• W3144539302 hasAuthorship W3144539302A5040778237 @default.
• W3144539302 hasAuthorship W3144539302A5043192106 @default.
• W3144539302 hasAuthorship W3144539302A5048817166 @default.
• W3144539302 hasAuthorship W3144539302A5060457096 @default.
• W3144539302 hasAuthorship W3144539302A5063479502 @default.
• W3144539302 hasAuthorship W3144539302A5069522355 @default.
• W3144539302 hasAuthorship W3144539302A5073520094 @default.
• W3144539302 hasAuthorship W3144539302A5076383043 @default.
• W3144539302 hasBestOaLocation W31445393021 @default.
• W3144539302 hasConcept C126322002 @default.
• W3144539302 hasConcept C141105273 @default.
• W3144539302 hasConcept C142724271 @default.
• W3144539302 hasConcept C159654299 @default.
• W3144539302 hasConcept C170493617 @default.
• W3144539302 hasConcept C199215989 @default.
• W3144539302 hasConcept C203014093 @default.
• W3144539302 hasConcept C204787440 @default.
• W3144539302 hasConcept C207480886 @default.
• W3144539302 hasConcept C27081682 @default.
• W3144539302 hasConcept C2776949755 @default.
• W3144539302 hasConcept C2779350572 @default.
• W3144539302 hasConcept C2779779143 @default.
• W3144539302 hasConcept C2780510475 @default.
• W3144539302 hasConcept C2908647359 @default.
• W3144539302 hasConcept C54355233 @default.
• W3144539302 hasConcept C6557445 @default.
• W3144539302 hasConcept C71924100 @default.
• W3144539302 hasConcept C86803240 @default.
• W3144539302 hasConcept C90924648 @default.
• W3144539302 hasConcept C99454951 @default.
• W3144539302 hasConceptScore W3144539302C126322002 @default.
• W3144539302 hasConceptScore W3144539302C141105273 @default.
• W3144539302 hasConceptScore W3144539302C142724271 @default.
• W3144539302 hasConceptScore W3144539302C159654299 @default.

• next